Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) by Emma K Larkin et al.
STUDY PROTOCOL Open Access
Objectives, design and enrollment results
from the Infant Susceptibility to Pulmonary
Infections and Asthma Following RSV
Exposure Study (INSPIRE)
Emma K Larkin1, Tebeb Gebretsadik2, Martin L Moore3, Larry J Anderson3, William D Dupont2, James D Chappell4,
Patricia A Minton1, R Stokes Peebles Jr1, Paul E Moore5, Robert S Valet1, Donald H Arnold5, Christian Rosas-Salazar5,
Suman R Das6, Fernando P Polack5, Tina V Hartert1* and On Behalf of the INSPIRE Study
Abstract
Background: Respiratory syncytial virus (RSV) lower respiratory tract infection (LRI) during infancy has been
consistently associated with an increased risk of childhood asthma. In addition, evidence supports that this
relationship is causal. However, the mechanisms through which RSV contributes to asthma development are not
understood. The INSPIRE (Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure) study
objectives are to: 1) characterize the host phenotypic response to RSV infection in infancy and the risk of recurrent
wheeze and asthma, 2) identify the immune response and lung injury patterns of RSV infection that are associated
with the development of early childhood wheezing illness and asthma, and 3) determine the contribution of
specific RSV strains to early childhood wheezing and asthma development. This article describes the INSPIRE study,
including study aims, design, recruitment results, and enrolled population characteristics.
Methods/design: The cohort is a population based longitudinal birth cohort of term healthy infants enrolled during
the first months of life over a two year period. Respiratory infection surveillance was conducted from November to
March of the first year of life, through surveys administered every two weeks. In-person illness visits were conducted if
infants met pre-specified criteria for a respiratory illness visit. Infants will be followed annually to ages 3-4 years for
assessment of the primary endpoint: wheezing illness. Nasal, urine, stool and blood samples were collected at various
time points throughout the study for measurements of host and viral factors that predict wheezing illness. Nested
case-control studies will additionally be used to address other primary and secondary hypotheses.
Discussion: In the INSPIRE study, 1952 infants (48% female) were enrolled during the two enrollment years and follow-
up will continue through 2016. The mean age of enrollment was 60 days. During winter viral season, more than 14,000
surveillance surveys were carried out resulting in 2,103 respiratory illness visits on 1189 infants. First year follow-up has
been completed on over 95% percent of participants from the first year of enrollment.
With ongoing follow-up for wheezing and childhood asthma outcomes, the INSPIRE study will advance our
understanding of the complex causal relationship between RSV infection and early childhood wheezing and asthma.
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Background
Prospective epidemiologic studies have consistently demon-
strated that infants with respiratory syncytial virus (RSV)
lower respiratory tract infections (LRIs) have an increased
risk of early childhood wheezing and asthma [1-5]. There is
also evidence from animal [6-10], human [8,11], and clinical
studies [12,13] that mild RSV infections may reduce the
risk of asthma development, presumptively by modulating
pathogenic immunity through early activation and expan-
sion of T regulatory cells. Intervention trials in humans
demonstrating that preventing infant RSV illness prevents
recurrent wheezing, and mechanistic studies in animal
models provide proof of concept and plausible mechanisms
through which RSV could cause asthma [14-17]. Additional
research demonstrates that the strain of RSV is associ-
ated with the clinical severity of acute infection
[18-20]. Thus, RSV may be an important organism
that modifies the developing immune system, differ-
ently, depending on the severity or host response to
the virus. This is important, as RSV prevention or
modulating host response to viral infection could re-
sult in a new target for primary asthma prevention.
The INSPIRE (Infant Susceptibility to Pulmonary In-
fections and Asthma Following RSV Exposure) study
builds upon the known links between RSV LRI and
wheezing illness to address unanswered questions
about the role of mild RSV infection in decreasing the
risk of childhood wheezing illness and host and viral
characteristics associated with wheezing or asthma fol-
lowing infant RSV infection.
Because we cannot yet predict which infants with RSV
LRI will ultimately develop childhood asthma and wheezing
illnesses, or who might most benefit from preventing early
viral infection [1,21,22], the INSPIRE study cohort was de-
signed to help understand how the complete spectrum
(mild to severe) of RSV illnesses contributes to early child-
hood wheezing and asthma. In particular, because there is a
paucity of studies on outpatient RSV, our study captures
mild RSV infections. This longitudinal cohort was specific-
ally designed to 1) establish the relationship between the
host phenotypic response to RSV infection in the first
6 months of life and the risk of recurrent wheeze and
asthma; 2) identify the host immune response determinants
of the RSV infection phenotype on the development of
early childhood wheezing and asthma following RSV infec-
tion; and 3) determine the contribution of specific RSV
strains to early childhood wheezing and asthma develop-
ment. Figure 1 depicts the conceptual framework that the
study is built upon.
This paper details the study aims, procedures, and re-
cruitment results from the INSPIRE study, a unique
birth cohort of over 1,900 term, healthy infants followed
longitudinally from infancy through early childhood for
the outcomes of wheezing illnesses and asthma, with de-
tailed characterization of respiratory illness during in-
fancy during RSV season. The study will identify host,
Figure 1 Hypothesis Testing: The epidemiologic triangle.
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viral and environmental factors associated with RSV in-




The study was designed to test two primary hypotheses:
1) the severity of RSV infection during infancy is associ-
ated with recurrent wheezing and early childhood
asthma in a severity-dependent manner and; 2) indices
of host immune response and lung injury associated
with infant RSV infection will differ among infants who
do and do not develop recurrent wheezing and early
childhood asthma.
Secondary objectives
The secondary objectives are to: 1) test the hypothesis
that specific RSV strains will be associated with differen-
tial LRI severity, recurrent wheezing and early childhood
asthma; 2) determine the association between all viral
infections (URIs only (mild) any LRI (severe)) and aller-
gic rhinitis (AR); 3) test the interactions between allergic
rhinitis/laboratory atopy and smoking, family history of
asthma, infant age at RSV infection with respiratory in-
fection severity; 4) assess the relationship between LRI
severity and allergic rhinitis within the LRI subgroup; 5)
determine the association of RSV infection severity with
recurrent wheezing and wheezing illness severity; 6) test
the hypothesis that there are RSV strain differences in
the pattern of cytokines in acute infection; 7) longitudin-
ally characterize the airway microbiome in early infancy,
during infant RSV acute respiratory illness (ARI), and at
2-3 years of age on a subset of children (n = 100); 8) de-
termine whether the specific patterns of airway micro-
biome diversity in early infancy (prior to RSV ARI),
during infant RSV ARI, and/or the change in pattern be-
tween health and RSV ARI are associated with respira-
tory outcomes of severity of RSV ARI in infancy and
subsequent development of wheezing illness in early
childhood; and 9) determine whether specific patterns of
airway microbial diversity in early infancy (prior to RSV
ARI), during infant RSV ARI, and/or the change in pat-
tern between health and RSV ARI are associated with
patterns T cell responses and innate cellular responses to
RSV stimulation at 2-3 years on a subset of infants.
Study design
To address primary hypothesis 1, we designed a longi-
tudinal observational birth cohort study of infants (the
INSPIRE cohort), enrolled over a two year period,
which included respiratory illness surveillance from
November 1 to March 31 during the infant’s first year
of life, and annual follow-up to the third or fourth
birthday. Primary hypothesis 2 will be addressed
through the use of a nested case-control study from
participants within the cohort.
Study population and subject recruitment
We enrolled and are longitudinally following 1952 term,
otherwise healthy infants from pediatric practices located in
Middle Tennessee, or self-referral through research an-
nouncements. The recruitment area encompasses urban,
suburban and rural areas. Infants meeting eligibility criteria
outlined in Table 1 were approached at time of a pediatric
visit to a participating practice. By design, infants whose
birthdays fell between June 1st and December 31st were
targeted for enrollment so that infants were on average
younger than 6 months of age during winter virus season,
when RSV infection is likely to both represent the first
and most severe infection. To meet recruitment mile-
stones and assure sufficient spectrum of disease severity
during the 2 recruitment seasons, infants were also en-
rolled during acute illnesses. The protocol and informed
consent documents were approved by the Institutional
Review Board at Vanderbilt University Medical Center.
One parent of each participant provided written in-
formed consent for participation in this study. The in-
formed consent document explained study procedures,
use of data of and biospecimens for future studies, in-
cluding a rider for genetic studies.
Study visits and procedures
Enrollment visit
At the baseline visit, trained study staff administered a
baseline questionnaire. The components of the study
visits are given in Table 2. The questionnaire included
demographic characteristics, infant medical history, family
history, secondhand smoke exposure, daycare attendance,
growth trajectory and other factors known to be associated
with childhood asthma and allergy development. Multiple
bio-specimens were collected for different purposes at each
time point and are described in Table 3. A urine sample
was collected at enrollment, through use of an exter-
nal bag, for markers of inflammation and lung injury.
In year 2, infant stool samples and nasal samples were
also collected at enrollment. The infant nasal samples
at enrollment were collected by insertion of filter
paper (Leukosorb™; Pall Corporation, Port Washing-
ton, NY) into each nostril, as described previously
[23,24]. A maternal finger stick was also collected in
year 2 to bank maternal blood samples for other as-
says, such as vitamin E isoforms.
Respiratory illness surveillance
Respiratory illness surveillance was conducted during the
winter virus season (November to March) of each infant’s
first year of life in order to capture and characterize infant
acute respiratory illnesses during RSV season. Respiratory
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illness surveillance had three components: first, parents
were instructed to call the research staff between Novem-
ber and March, at first onset of respiratory symptoms
which included any one of the following: runny nose, con-
gestion, wheezing, fever and/or cough at which time the
screening respiratory illness survey was completed. Second,
all enrolled infants who were seen for an acute visit at their
pediatric practice were approached and administered the
respiratory illness survey. Third, every two weeks, from
November through March, parents received regular
contact by an e-mail secure survey or telephone call to
complete the respiratory illness survey. The respiratory
illness survey is a series of questions about respiratory
symptoms and time of onset.
Table 1 Inclusion and Exclusion Criteria for Enrollment in
INSPIRE Study
Inclusion criteria: Exclusion criteria:
Singleton birth to a mother 18
years or older.
Need for mechanical ventilation
prior to enrollment
Born at ≥ 37 weeks gestation Significant cardiopulmonary disease
Birth weight ≥ 2250 g (5 lbs.) Bronchopulmonary dysplasia
Born June 1 – December 31








No intent to relocate from
Nashville and surrounding
area within 5 years
Neurological disease
Any other health condition that
may jeopardize the integrity of data
to be collected during the study
Table 2 INSPIRE Main Study Schedule




Visit Type Survey Nasal Urine Fecal LPS
Wipe
Blood Allergy








Well Child Visits June – Dec 2013 June – Dec 2014 1st Annual Visit X X X
June – Dec 2014 June – Dec 2015 2nd Annual Visit X
June 2015 –June 2016** 2-3 Year Sub-Study
(n = 100)**
X X X X
PBMC**
June – Dec 2015 June – Dec 2016 3rd Annual Visit X X
June – Dec 2016 4th Annual Visit X
*included in second year cohort enrollment only.
**Sub-study of microbiome on subset of children; PBMC = Peripheral Blood Mononuclear Cells.
Nasal = Filter paper at baseline and nasal wash at time of respiratory illness.
Blood =Maternal finger stick at baseline and infant venipuncture or finger/toe stick at 1 year.
Allergy = Skin prick testing for aeroallergens or venipuncture for serum allergen-specific IgE.
Table 3 Specimen Repository for INSPIRE Study
Time Point and Sample
Type
A priori testing planned
Baseline:




Infant stool sample* Gut microbiome
Maternal plasma* Vitamin E levels
Respiratory Illness:
Infant urine Markers of inflammation and lung injury
Infant nasal wash PCR identification of RSV or RV; cytokines and
biomarkers of immune function; microbiome.
RSV positive samples will be sequenced.
One Year:







Immune response to RSV stimulation
Child nasal wash Nasal microbiome
Child stool sample Gut microbiome
Three Year:
Child blood Serum allergen-specific IgE measurements;
if skin prick testing not possible
Bold indicates study time point.
*Collected only in second year of enrollment.
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Acute respiratory illness visits
Infants met our case definition of a respiratory illness
visit based on responses to the respiratory illness sur-
veillance questionnaires: a parent indicates ONE of the
following major symptoms or diagnoses: wheezing,
difficulty breathing, or told that your baby had a posi-
tive RSV test OR ANY TWO of the following minor
symptoms or diagnoses: fever, runny nose/congestion/
snotty nose, cough, ear infection (otitis media), or
hoarse cry. Onset of symptoms must have been in the
prior week (the past 5 days for the infants enrolled in
year 1 of the study, and the prior 7 days for infants en-
rolled in year 2 of the study). This change in symp-
tom/diagnosis window was made to accommodate
missing respiratory visits because of no staffing on
weekends.
If the infant met pre-specified criteria for a respiratory
illness visit, an in-person visit was performed either in
the clinic, the pediatric clinical research center, or the
infant’s home. The visit included a brief physical exam
with elements that measure the severity of respiratory
infection: respiratory rate, oxygen saturation/heart
rate, wheezing, and chest retractions. Chart review
was used to supplement the research exam with infor-
mation about doctor diagnosis, when a healthcare visit
occurred. The respiratory symptom assessment de-
tailed the symptoms present and the date of onset. In
addition, a nasal wash and urine sample were collected
at each respiratory illness visit. A nasal wash was con-
ducted using 5 mL of sterile saline solution and imme-
diately placed at 4 degrees Celsius. The nasal washes
were aliquoted and snap frozen at -80 degrees within
24 hours of collection.
1-year study visit
The one year follow-up visit was conducted between 9 –
15 months of age and included questions about respira-
tory health and exposures, and a venipuncture for RSV
serology. If the caregiver refused venipuncture or blood
was not able to be drawn, research staff collected 250 μL
of blood from a toe or finger stick. If consent was given
for genetic studies, a buffy coat sample was banked for
future DNA extraction. Participants were also asked to
collect household dust samples by wiping the top of the
doorframe of the room where the infant sleeps with 2
wipes (TefTex™, Dalla Lana School of Public Health,
University of Toronto, Toronto, Canada) and returning
by mail [25]. These samples are to be used for endo-
toxin/lipopolysaccharide measurements [25,26].
Annual visits
Annual follow-up study contact is ongoing and will take
place at year 2, 3 and 4. Year 2 and 4 follow-up is by
telephone survey and includes the International Study of
Asthma and Allergy in Children (ISAAC) [27] and other
allergic disease and respiratory disease questionnaires.
The third year visit is in-person and includes the above
components, as well as skin prick testing to aeroallergens
common to the region, or if skin testing cannot be per-
formed, a blood draw for measurement of specific IgE to
the same aeroallergens.
Study endpoints
The co-primary study endpoints are both recurrent
wheezing and early childhood asthma. Recurrent wheez-
ing is defined between ages 1-3 years, as two or more
wheezing episodes at any time during that period. Early
childhood asthma will be determined at age four using
elements of the ISAAC questionnaire. Children who
meet both of the following criteria at age four will be
classified as definite early childhood asthmatics: (1) 12-
month prevalence of asthma symptoms or exercise-
induced wheeze or dry cough at night, AND (2) physician
diagnosis by parental report or use/prescription of asthma
medications [27-36]. Children who meet just one of the
two criteria will be considered to have probable early
childhood asthma.
Secondary endpoints
Respiratory illness severity at time of illness will be mea-
sured by an ordinal scale based on wheezing, respiratory
rate, retractions, and oxygen saturation or heart rate,
modified from scores derived for LRI [37]. Also, a di-
chotomous outcome, LRI versus URI will be used to
measure severity. Allergic rhinitis (AR) diagnosis will
also be made using elements of the ISAAC question-
naire. Children will be considered to have definite aller-
gic rhinitis (AR) if each of three conditions are present
at age four: (1) a history of nasal congestion, runny nose,
itchy watery eyes, sneezing, or blocked nose; AND (2)
substantial variability in symptoms over time or season-
ality; AND (3) diagnosed as having AR by a physician or
on medications for AR. Patients will be considered to
have probable AR if they report symptoms as outlined
above in (1) and (2) but have not been diagnosed or
treated by a physician. Atopic dermatitis diagnosis will
be confirmed through the ISAAC core questions on
atopic dermatitis, which are based on a list of major and
minor criteria proposed by Hanifin and Rajka in the
1970s [32,38,39]. Patients will be classified as definite
atopic dermatitis if they report ever having an itchy rash
that comes and goes for at least six months, AND being
diagnosed with eczema by physician documentation.
They will be classified as probable atopic dermatitis if
they report one of the two above criteria. Atopy will be
assessed by either a positive skin prick allergen test for
aeroallergens (preferred) or specific IgE from blood test
at age 3 years: 1) Positive skin prick testing is defined by
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a wheal (center raised part) of 3 mm or greater to one of
the aeroallergens (when histamine control is positive
and the saline control is negative [non-reactive], indicat-
ing that the patient is not dermatographic [i.e. reacting
to irritation and not to specific allergens]), or 2) labora-
tory atopy will be defined as specific IgE > 0.1 PAU/L to
at least one common aeroallergen performed on blood
specimens collected at 3-years. Additional secondary
endpoints will be defined by breaking down co-primary
recurrent wheezing outcome into well-accepted asthma
phenotypes [40], including: 1) transient early wheezing
will be defined as wheezing episodes during the first
three years of life [41]. 2) persistent wheezing will be
defined as wheezing during the first three years and be-
yond. 3) Late onset wheezing will be defined as wheezing
not present in the first three years, but with symptoms
beginning between three and four years.
Primary exposure
Singleplex reverse-transcription real-time PCR assays for
RSV, human rhinovirus, human enterovirus, and human
ribonuclease P (RNAseP) in nasal washes were performed
according to published protocols [42,43]. RNAseP served as
an endogenous control for specimen quality, and specimens
failing to demonstrate an RNAseP signal among multiple
individually processed aliquots were deemed indeterminate
for viruses not detected in repetitive testing. Efficiency of
nucleic acid extraction was monitored through amplifica-
tion of RNAseP in cultured human-cell lysates incorporated
into each round of specimen processing. Results of amplifi-
cation reactions were validated by expected findings for
water blanks, negative controls, and positive controls de-
rived from viral culture lysates (adjusted to concentrations
representative of patient specimens) included in each PCR
reaction plate. RSV IgG antibodies will be assessed at one
year by four enzyme immunoassays (EIA). One EIA using
RSV A2 (group A strain) lysate as the antigen, one using
RSV B1 (group B strain) lysate, one using an RSV group A
G protein peptide (RSV A2 aa 161-190 : NDFHFEVFNF
VPCSICSNNP TCWAICKRIP), and one using an RSV
group B G protein peptide (RSV B1 aa 161-190 : DDYH-
FEVFNF VPCSICGNNQ LCKSICKTIP). RSV serology at
year one, coupled with viral identification of RSV by PCR
at time of respiratory illness, will be used to determine
whether infants were exposed to RSV.
Biomarkers analyzed during acute respiratory illness
Additional biomarkers analyzed during acute respiratory
illness will also serve as primary endpoints for analyses.
Lung injury and host immune response will be measured
in urine samples collected during the acute respiratory
illness and include cysteinyl leukotrienes, CC-16, KL-6,
IL-18, TNF-α, HNE, prostacyclin, and isoprostanes. Im-
mune function biomarkers assayed from nasal washes
collected during acute respiratory illness include: VEGF,
G-CSF, EGF, FGF, eotaxin, eotaxin-2, eotaxin-3, MCP-2,
BCA-1, MCP-4, I-309, IL-16, TARC, X6CKine, LIF,
TPO, SCF, TSLP, IL-33, IL-20, IL-21, IL-23, TRAIL,
CTACK, SDF-1a-b, ENA-78, MIP-1d, IL-28A, IL-1B, IL-
10, IL-13, IL-6, IL-12, RANTES, IL-17, MIP-1a, GM-
CSF, MIP-1B, MCP-1, IL-15, IL-5, IFN-y, IFN-a, IL-1RA,
TNF-a, IL-2, IL-7, IP-10, IL-2R, MIG, IL-4, IL-8, HGF
and Muc5ac.
Planned statistical analyses
Descriptive analysis of infant demographic, clinical and
biological measurements will be performed using means
and standard deviations or medians and inter-quartile
ranges for continuous variables, and proportions for cat-
egorical variables.
Cohort study
Our first hypothesis examines whether the severity of
RSV infection is associated with risk of early childhood
wheezing or early childhood asthma. RSV exposure is
determined by confirmed RSV illness by PCR, and/or
positive 1-year RSV serology. The co-primary endpoints
will be recurrent wheezing and early childhood asthma
as described previously. Logistic regression will be used
to estimate the odds ratio (OR) and 95% confidence in-
tervals [44] of developing childhood asthma or recurrent
wheezing in children with severe or mild RSV infection
relative to those who were not infected in infancy. Both
crude ORs and ORs adjusted for confounding variables
will be derived. Confounding variables for our multiple
logistic regression models will include maternal age, in-
fant age at first RSV infection, gestational age, second-
hand smoke (SHS), infant sex, and family history of
allergic diseases. Other confounding variables to be con-
sidered include further detail on home environment, in-
cluding infant diet, use of acetaminophen or NSAIDs,
study year, gender, and family history of asthma. A priori
interaction terms will be included in our models and we
will examine their effect on the change of model devi-
ance. Additional analyses will be conducted to assess
model fit. These will include scatter plots of squared
standardized Pearson residuals against the estimated
asthma probability for patients with each covariate pat-
tern. Analyses will be conducted using SAS (SAS Insti-
tute Cary, NC) and R (http://www.r-project.org).
Nested case-control study
To test our hypothesis that measures of host immune
response and lung injury will differ between infants with
RSV illness who do and do not develop recurrent wheez-
ing or early childhood asthma, we will conduct nested
case-control studies of incident early childhood asthma
cases following infant RSV infection to matched RSV-
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infected children who do not develop recurrent wheez-
ing or asthma. Two controls will be selected for each
case as follows: First, we will fit a logistic regression
model in which asthma outcome is regressed against
these matching covariates. The coefficients from this
model will be used as weights to create an asthma risk
score for each subject, which is the weighted sum of
these risk covariates. Controls will then be frequency
matched to cases based on their asthma risk score. This
risk score will be derived from one of our prior analyses
of an administrative data set that used a regression ana-
lysis [45].
Power calculations
Primary Hypothesis 1: Power calculations were per-
formed before the study began. The primary outcome
for this study is recurrent wheezing illness at age 3-4, ra-
ther than asthma, which requires more time for follow-
up than allowed during the grant funding period. Our
power calculations were based on a birth cohort of 1500
infants plus a total of 400 infants recruited at the time of
RSV infection in infancy for a total of 1900 children.
Two thirds of these 400 were assumed to have severe
RSV disease necessitating hospitalization while one-third
to have mild disease treated on an outpatient basis. We
anticipated that 75% of the subjects will be successfully
followed up to measure asthma outcomes at 4-6 years of
age. We have powered our primary hypothesis with RSV
exposure levels of 20% of infants with LRI, 40% URI and
40% with no RSV infection in their first year of life. We
further assumed a conservative estimate of 11% infants
who were not exposed to RSV to develop asthma at ages
4-6 years. We performed power calculations based on a
2-sided test of the null hypothesis that the asthma preva-
lence was not affected by infant RSV exposure, with a
Type I error probability of α = 0.05. In Figure 2, the red
curve shows the power for different asthma odds ratios
for infants with RSV LRI relative to those with no infec-
tion. We expect that the prevalence of asthma among
infants with URI (mild) will be 7% and the dashed blue
curve in Figure 2 shows the asthma odds ratios for in-
fants with no exposure vs. mild infection. The preva-
lence of recurrent wheezing is expected to be much
higher than the asthma prevalence shown, thus we ex-
pect to have ample power for our analysis. We anticipate
that 30% of the entire cohort will have recurrent wheez-
ing at three years of age. This will provide us with con-
siderably more power to detect different odds ratios for
Figure 2 Power for primary hypothesis 1 to assess the association between RSV exposure and asthma based on 1900 infants with 25%
attrition (α = 0.05).
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wheezing than we will attain for asthma, as shown in
Figure 2. These power calculations show we will have at
least 80% power to detect recurrent wheezing relative
risks greater than 1.65 or less than 0.61 in subgroups of
infants defined by RSV exposure and assuming 75% fol-
low up.
Primary Hypothesis 2, Nested Case-Control Study:
Preliminary data from previous studies provide estimates
of selected biomarkers, including leukotrienes, CC-16,
KL-6, IL-18, TNF-α, and HNE. Estimates of minimal
detectable differences (two sided α = 0.05) are given in




An overview of the recruitment is presented in Figure 3.
1952 infants were enrolled: 861 infants in the first year
and 1091 in the second year. We approached 83% of
eligible infants (3559/4381) for enrollment with 55%
agreed to participate (1952/3559). The most common
reason participants provided for not enrolling was that
they were “not interested” (63%; n = 685/1085). Five
hundred and twenty-two parents received brochures and
study information, but decided not to enroll at the time
of visit. In this situation, we were not able to establish
contact again, despite a continued presence at their
pediatrician’s office and do not know the reason for non-
enrollment. At the time of this publication, 82 participants
have withdrawn from the study, most commonly due to an
unexpected move out of Middle Tennessee (N = 21). The
second most common reason was discomfort with the 1-
year blood draw (N = 18). For those willing to participate
after moving, a blood sample will be collected, processed
and shipped, and the annual case report form will be ad-
ministered by telephone.
Demographic characteristics of the sample are shown
in Table 5. Approximately 93% percent of our partici-
pants were enrolled from 8 pediatric practices, where
staff was located on-site throughout the study. The
remaining visits were performed at the Vanderbilt
Pediatric Clinical Research Center (PCRC). Eight percent
(164/1952) of infants had an acute respiratory infec-
tion at the time of enrollment. Among those age-
eligible for the 1-year visit, 85% have been completed
as of December 15, 2014.
Acute respiratory illness surveillance
Over the two respiratory seasons between November
through March, 14,285 respiratory surveillance contacts
were completed through e-mail, telephone or in-person
on 1,943 individuals (9 individuals never responded).
The median time between contacts was 14 days with an
interquartile range (IQR) of 12.6-15.6 days. The median
number of responses per individual was 8 (IQR: 6-10.5).
5,200 survey respondents reported symptoms within the
past 5 days; however, only 2,516 met criteria for an acute
respiratory illness visit by either 1 major symptom or 2
minor symptoms.
Respiratory illness visits
2,103 respiratory illness visits were completed on 1,189
infants, with 2,036 nasal washes collected and stored. Of
these 61% of infants had one or more respiratory illness
visits. 682 infants had 1 visit, 314 had 2 visits, 149 had 3
visits and 78 had 4 or more visits. Urine was collected
during 1652 (79%) respiratory illness visits. 385 (19%) in-
fant respiratory illness visits were RSV positive based on
PCR of nasal washes. Blood was banked for RSV ser-
ology testing on 1-year infant samples.
Longitudinal follow-up
At the time of this publication, 2-year telephone calls
are ongoing for those recruited in the first year of enroll-
ment and 1-year visits are ongoing for infants enrolled
in the second year. We have completed approximately
95% of the 1-year follow-up visits for first year of enroll-
ment, after excluding withdrawals (760/805).
Discussion
Currently, INSPIRE is the largest population based pro-
spective epidemiologic study where the spectrum of se-
verity of RSV infection illnesses are assessed in
relationship to recurrent wheezing illnesses and asthma
onset. Asthma is a multifactorial disease with onset,
course and severity reflecting the combined effects of
development-specific exposures in utero and post-
natally, and the host responses to those exposures. RSV
is one of these ubiquitous exposures, which as an infec-
tious agent likely works through differentially modifying
the developing immune system and lung, based on spe-
cific strains, severity of infection, and host response to
infection. The first primary study hypothesis uses the en-
tire cohort to determine the relationship between the
spectrum of RSV exposure to severe infection on risk of
wheezing illness in childhood. While severe LRI has
Table 4 Nested case-control study, minimal detectable
differences of biomarkers under different hypothetical
assumptions with 1:2 case-control matching












Urinary PGI 175 pg/mL
(12.1)
4.6 3.2
* Based on references [46-50].
Larkin et al. BMC Pulmonary Medicine  (2015) 15:45 Page 8 of 12
been linked to development of wheezing or asthma
[1-5,51], little is known about the role of mild infection.
The INSPIRE study was designed to address gaps in
our knowledge about the role of the host immune response
and lung injury to RSV infection in asthma inception, and
to understand how viral strain differences contribute to in-
fant morbidity and asthma risk. This will be done through
the second study hypothesis that utilizes a nested case-
control design within the total cohort. This design will
identify host immune and lung injury markers that are dif-
ferentially associated with outcomes of wheezing illnesses
at ages 3-4, and eventually childhood asthma at age 6. Our
hypothesis is based on evidence that host responses are as-
sociated with increased risk of severe RSV LRI. Among in-
fants with severe RSV infection, TNF-α and eosinophil
active cytokines are elevated compared to non-ill infants
[52] or mildly ill infants [53,54] and correlate with the se-
verity of illness [55]. After RSV LRI, cysteinyl leukotrienes
and IL-17 remain elevated in nasal epithelium [53,56], and
IL10 production and genetic variants IL-13, IL-19 and IL-
20 are associated with post-bronchial wheeze [57-60]. RSV
infection may also cause harmful remodeling of infant
lungs [40]. Infant lungs are not fully developed at birth;
changes in airway epithelium and alveolarization continue
through the first two years of life [61]. Animal studies
have shown increased airway hyper-responsiveness
and decreased neuronal relaxation after experimental
RSV infection [62]. The INSPIRE study will bridge
what is known about the immune response at time of
infection and extend to 3-4 year outcomes of wheezing
illnesses. RSV strains from infants in INSPIRE will be
sequenced to determine if strain differences are asso-
ciated with acute infection morbidity in infancy and
later wheezing outcomes.
Prior studies of infant RSV infection have focused al-
most exclusively on the 3-5% of infants hospitalized with
RSV LRI. Most infants, however, have milder RSV infec-
tion, and the majority of those who do develop RSV LRI
do not develop asthma. While severe LRI has been
clearly linked to the development of asthma, an import-
ant unanswered question is whether mild RSV infection
confers intermediate risk or may actually protect against
the inception of childhood asthma. If mild RSV infection
primes the immune system or confers a protective effect
against future wheezing illnesses, this has important im-
plications for the development of RSV vaccines and RSV
immunoprophylaxis. Thus, there are compelling reasons
to focus on the development of new approaches to un-
derstanding why certain infants are predisposed to de-
veloping viral LRI, and which children with RSV LRI
develop subsequent childhood asthma.
Strengths of our study include biweekly surveillance to
capture the full spectrum of respiratory infections, in-
cluding even mild infections by regular surveillance in-
tervals, and serologic confirmation of infant infection to
identify those who are infected and those who are
Figure 3 Flowchart of INSPIRE Study, through December 15, 2014.
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unexposed. The location of research staff at pediatric
clinics allowed frequent contact with participants
throughout winter virus season. We also have a large re-
pository of banked urine samples during enrollment and
acute illness, 1-year plasma samples, DNA, stool sam-
ples, acute illness nasal washes, and baseline enrollment
nasal filter paper samples.
This study has several limitations that are important
to consider. First, the study sample was not selected
from the general population, but instead was recruited
from participating pediatric clinics in the city of
Nashville and surrounding counties; however, we
attempted enrollment of all births at these clinics
meeting criteria. Our study cohort demographics rep-
resent a varied population demographic that reflects
the diversity of the community from which the cohort
is recruited. Surveillance for respiratory illnesses oc-
curred during a full 5-month period. However, surveil-
lance was by biweekly surveys or self-reporting, and
illnesses may have been missed or not reported. In
addition, the respiratory illness visits may have oc-
curred up to 7 days after onset of symptoms, thus
characterization of the illness severity at the visit may
not reflect the time when the illness was most severe.
Although we decided to include an enrichment sample
of infants with acute respiratory infections at the
emergency room or hospital admission, this was not a
major source of enrollment because many of these
participants were not able to fulfill the longitudinal
study requirements primarily due to large distances to
our study site.
This study was funded by a National Institute of
Allergy and Infectious Diseases (NIAID) Asthma and Aller-
gic Diseases Cooperative Research Center (AADCRC) grant
that also supports three related projects that will in-
vestigate key disease mechanisms, and utilize samples
from this cohort. (1) The first project aims at identify-
ing the molecular basis for RSV strain differences
associated with mild and severe RSV respiratory infec-
tion. To do this, collaborators at Emory University
School of Medicine (MLM, LJA) and J. Craig Venter
Institute (SRD) will genotype RSV isolates of the IN-
SPIRE cohort in order to identify RSV genotypes asso-
ciated with bronchiolitis severity, childhood wheeze,
and the development of asthma. (2) A second project
will study the role of PGI2 in a mouse model of re-
spiratory syncytial virus (RSV) infection (RSP). The ul-
timate goal is to determine if targeted therapies of the
host immune response could prevent or treat severe
RSV bronchiolitis and the subsequent development
of asthma. (3) A third project is the longitudinal
characterization of the infant and early childhood
microbiome during health and acute respiratory ill-
ness, and the association of microbial diversity with
both infant acute respiratory illness severity and child-
hood wheezing outcomes (TVH, CRS, and SRD).
In summary, this ongoing study will answer import-
ant questions about the mechanisms through which
RSV causes acute and long term respiratory morbidity.
This methodology paper outlines the study questions
addressed, how the birth cohort (INSPIRE) was de-
signed to address these questions, and provides pre-
liminary enrollment data. Our unique study design
targets infants born from June to December, such that
they are on average 6 months of age during RSV circu-
lation. With well-characterized respiratory infections
during infancy, we are poised to address important
questions about the causal role of RSV infection in the
development of childhood wheezing and early child-
hood asthma. In addition to a carefully phenotyped
cohort, we have a rich biospecimen repository. Our fu-
ture plans include following this cohort to childhood
asthma outcomes at age 6, characterizing the host re-
sponses to infection which are associated with protec-
tion from or risk of asthma, and understanding other
associated risk factors including host genetics.
Table 5 Demographic Characteristics of Infants in the
INSPIRE Study
Baseline demographics N = 1952
Race, n (%)
White Non-Hispanic 1269 (65%)





Sex, n % Male 1021 (52%)
Mean infant age at enrollment in days, (SD) 59.6 (51.5)
Currently breastfeeding at enrollment, n (%) 1018 (52%)
Mean gestational age in weeks, (SD) 39.1 (1.1)
Mean birth weight in grams (SD) 3425 (515)
Exposure to Prenatal Smoking, n (%) 352 (18%)
Maternal asthma, n (%) enroll 380 (19%)





Mother employment status, n (%)
Full Time 862 (44%)
Part Time 403 (21%)
Not Employed 679 (35%)
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